Roche Diagnostics (SWX: ROG), the Swiss diagnostics heavyweight, has furthered its collaboration with Beijing Strong Biotechnologies Inc. (SHE: 300406), a Chinese partner, to craft more holistic and pioneering laboratory solutions for hemostasis and thrombotic disorders. Building on their initial partnership established in 2016, which focused on biochemical reagents and resulted in the launch of a second-generation biochemical reagent kit at the 2021 China International Import Expo (CIIE), Roche Diagnostics and Strong Bio have now advanced their efforts to develop a fibrinogen degradation products (FDP) detection system.
This latest development in their partnership signifies a commitment to innovation in diagnostics, aiming to enhance the detection and management of hemostasis and thrombotic diseases, which are critical in the field of cardiovascular medicine.- Fineline.com
